R&D Network
Our pipeline forms a robust portfolio of investigational
therapies in varied stages of clinical development.

R&D Network

Hanmi R&D network consists of 6 sites creating a synergistic effect. Fully integrated 3 R&D Centers in Dongtan (Korea), Paltan (Korea), and Beijing (China) focus on new drug discovery and formulation research. Seoul R&D Center in our headquarters performs clinical research, regulatory affairs and licensing business. In addition, there are two process development research sites for biologics and chemical APIs.

R&D Network Table
NAME Location Major Fields of Research Number of Personnel
Hanmi R&D Center Dongtan, Gyeonggi-do in Korea New biological drugs, New chemical drugs 150+
Seoul R&D Center (Headquarters) Songpa-gu, Seoul in Korea Clinical studies, Regulatory affairs, Licensing in & out 110+
Pharmaceutical R&D Center Paltan, Gyeonggi-do in Korea New medicines, Drug transfer platform technology 60+
Bioprocess Research Center Pyeongtaek, Gyeonggi-do in Korea Manufacturing and development of recombinant protein products 50+
Hanmi Fine Chemical Central Research Institute Sihwa, Gyeonggi-do in Korea Mass production of active pharmaceutical ingredients 50+
Beijing Hanmi Research Center Beijing in China New bispecific antibodies 120+